GT BIOPHARMA, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
GT BIOPHARMA, INC. (GTBP) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 59.55 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-14
- GT BIOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 67.72M shares, a 3474.32% increase year-over-year.
- GT BIOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 1.89M shares, a 339.33% increase year-over-year.
- GT BIOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 431.23K shares, a 2.54% increase year-over-year.
- GT BIOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 420.56K shares, a 87.34% decline year-over-year.
- GT BIOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 57.98M shares, a 4556.75% increase from fiscal 2024.
- GT BIOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 1.25M shares, a 188.72% increase from fiscal 2023.
- GT BIOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 431.23K shares, a 226.05% increase from fiscal 2022.
- GT BIOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 132.26K shares, a 94.99% decline from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 59.55M shares 10-Q · filed 2026-08-14 | |||||||
| 2026-03-31 | 67.72M shares 10-Q · filed 2026-05-15 | |||||||
| 2025-12-31 | 57.98M shares 10-K · filed 2026-03-02 | |||||||
| 2025-09-30 | 57.71M shares 10-Q/A · filed 2026-03-06 | |||||||
| 2025-06-30 | 19.96M shares 10-Q · filed 2026-08-14 | |||||||
| 2025-03-31 | 1.89M shares 10-Q · filed 2026-05-15 | |||||||
| 2024-12-31 | 1.25M shares 10-K · filed 2026-03-02 | |||||||
| 2024-09-30 | 1.24M shares 10-Q/A · filed 2026-03-06 | |||||||
| 2024-06-30 | 1.26M shares 10-Q/A · filed 2026-03-06 | |||||||
| 2024-03-31 | 431.23K shares 10-Q · filed 2025-05-15 | |||||||
| 2023-12-31 | 431.23K shares 10-K · filed 2025-02-21 | |||||||
| 2023-09-30 | 429.56K shares 10-Q · filed 2024-11-14 | 12.89M shares 10-Q · filed 2023-11-01 | ||||||
| 2023-06-30 | 429.56K shares 10-Q · filed 2024-08-14 | 12.89M shares 10-Q · filed 2023-08-07 | ||||||
| 2023-03-31 | 420.56K shares 10-Q · filed 2024-05-15 | 12.62M shares 10-Q · filed 2023-05-15 | ||||||
| 2022-12-31 | 132.26K shares 10-K · filed 2024-03-26 | 3.97M shares 10-K · filed 2023-03-30 | ||||||
| 2022-09-30 | 4.47M shares 10-Q · filed 2023-11-01 | |||||||
| 2022-06-30 | 3.13M shares 10-Q · filed 2023-08-07 | |||||||
| 2022-03-31 | 3.32M shares 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | 2.64M shares 10-K · filed 2023-03-30 | |||||||
| 2021-09-30 | 2.34M shares 10-Q · filed 2022-10-31 | |||||||
| 2021-06-30 | 2.37M shares 10-Q · filed 2022-08-15 | |||||||
| 2021-03-31 | 1.60M shares 10-Q · filed 2022-05-16 | 5.32M shares 10-Q · filed 2021-05-17 | ||||||
| 2020-12-31 | 9.98M shares 10-K · filed 2022-03-28 | |||||||
| 2020-09-30 | 5.48M shares 10-Q · filed 2021-11-10 | 114.89M shares 10-Q · filed 2020-11-13 | ||||||
| 2020-06-30 | 127.95M shares 10-Q/A · filed 2020-08-18 | 5.48M shares 10-Q/A · filed 2021-12-29 | 127.95M shares 10-Q · filed 2020-08-14 | |||||
| 2020-03-31 | 5.48M shares 10-Q · filed 2021-05-17 | 87.12M shares 10-Q · filed 2020-05-15 | ||||||
| 2019-12-31 | 4.71M shares 10-K · filed 2021-04-16 | 86.97M shares 10-K · filed 2020-03-27 | ||||||
| 2019-09-30 | 73.52M shares 10-Q · filed 2020-11-13 | |||||||
| 2019-06-30 | 39.42M shares 10-Q/A · filed 2020-08-18 | 39.42M shares 10-Q/A · filed 2020-08-18 | ||||||
| 2019-03-31 | 22.73M shares 10-Q · filed 2020-05-15 | |||||||
| 2018-12-31 | 8.68M shares 10-K · filed 2020-03-27 | |||||||
| 2018-09-30 | 2.98M shares 10-Q · filed 2019-11-14 | |||||||
| 2018-06-30 | 3.39M shares 10-Q · filed 2019-08-14 | 1.70M shares 10-Q · filed 2018-08-14 | ||||||
| 2018-03-31 | 4.55M shares 10-Q · filed 2019-05-15 | 1.70M shares 10-Q · filed 2018-05-15 | ||||||
| 2017-12-31 | 1.16M shares 10-K · filed 2019-03-29 | 1.16M shares 10-K · filed 2018-03-01 | ||||||
| 2017-09-30 | 1.51M shares 10-Q · filed 2017-11-14 | 1.51M shares 10-Q · filed 2018-11-14 | ||||||
| 2017-06-30 | 1.03M shares 10-Q · filed 2018-08-14 | |||||||
| 2017-03-31 | 848.12K shares 10-Q · filed 2018-05-15 | 254.43M shares 10-Q · filed 2017-04-28 | ||||||
| 2016-12-31 | 126.14K shares 10-K · filed 2018-03-01 | 37.84M shares 10-K · filed 2017-03-31 | ||||||
| 2016-09-30 | 128.03K shares 10-Q · filed 2017-11-14 | 38.41M shares 10-Q/A · filed 2018-02-28 | ||||||
| 2016-06-30 | 12.90M shares 10-Q/A · filed 2018-02-28 | |||||||
| 2016-03-31 | 1.14M shares 10-Q/A · filed 2018-02-28 | |||||||
| 2015-12-31 | 12.53M shares 10-K/A · filed 2018-02-28 | |||||||
| 2015-09-30 | 2.04M shares 10-Q/A · filed 2018-02-28 | 509.87M shares 10-Q · filed 2015-11-13 | ||||||
| 2015-06-30 | 1.68M shares 10-Q/A · filed 2018-02-28 | 419.29M shares 10-Q · filed 2015-08-14 | ||||||
| 2015-03-31 | 3.41M shares 10-Q/A · filed 2018-02-28 | 852.51M shares 10-Q · filed 2015-05-14 | ||||||
| 2014-12-31 | 3.09M shares 10-K/A · filed 2018-02-28 | 773.18M shares 10-K · filed 2015-03-31 | ||||||
| 2014-09-30 | 0.00 shares 10-Q · filed 2015-11-13 | 835.64M shares 10-Q · filed 2015-01-08 | ||||||
| 2014-06-30 | 0.00 shares 10-Q · filed 2015-08-14 | 592.48M shares 10-Q · filed 2015-01-08 | ||||||
| 2014-03-31 | 627.47M shares 10-Q · filed 2015-01-08 | |||||||
| 2013-12-31 | 676.37M shares 10-K · filed 2015-03-31 | |||||||
| 2013-09-30 | 528.00M shares 10-Q · filed 2014-12-17 | |||||||
| 2013-06-30 | 471.72M shares 10-Q · filed 2014-12-12 | |||||||
| 2013-03-31 | 409.44M shares 10-Q · filed 2014-12-10 | |||||||
| 2012-12-31 | 686.72M shares 10-K · filed 2015-01-08 | |||||||
| 2012-09-30 | 538.29M shares 10-Q · filed 2012-11-21 | |||||||
| 2012-06-30 | 595.75M shares 10-Q/A · filed 2012-09-13 | |||||||
| 2011-12-31 | 225.84M shares 10-K · filed 2014-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |